|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SAN FRANCISCO , May 5, 2019 /PRNewswire/ -- Recently, the interactive touchscreen projector Puppy Cube was launched on Amazon.com and shipped by Amazon, with a retail price of $999 . At present, the official ...
Moody's Investors Service ("Moody's") assigned a Baa1 rating to the proposed senior unsecured notes offering of Zoetis Inc. ("Zoetis"). There are no changes to Zoetis' existing ratings including the Baa1 senior unsecured rating and the Prime-2 commercial paper rating. Proceeds from the notes offerings will be used to repay short term debt that was used in financing the acquisition of Abaxis, Inc. and for general corporate purposes.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 16. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK , July 31, 2018 /PRNewswire/ -- Triumph Bancorp Inc. (NASD: TBK) will replace Abaxis Inc. (NASD: ABAX) in the S&P SmallCap 600 effective prior to the open of trading on Monday, August 6 . S&P ...
With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want access to our free research report on Zoetis Inc. (NYSE: ZTS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZTS as the Company's latest news hit the wire. On July 06, 2018, the Company announced that it has completed the acquisition of Abaxis, Inc. (NASDAQ: ABAX), which is a leader in the development, manufacture, and marketing of diagnostic instruments for veterinary point-of-care services, for $83.00 per share in cash, or approximately $2.0 billion in total.
On July 6, Zoetis (ZTS) and Abaxis (ABAX) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Zoetis Inc. (ZTS) and Abaxis, Inc. (ABAX) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Zoetis’ previously-announced acquisition of Abaxis for US $83.00 per share in cash, or approximately $2.0 billion in aggregate. The expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transaction. The transaction is subject to other customary closing conditions, including the approval of Abaxis shareholders.
We are upbeat about Abaxis' (ABAX) solid consumable and instrument sales growth along with strength in the medical and veterinary market segments.